[go: up one dir, main page]

CN101801380A - 血管舒缩症状的治疗 - Google Patents

血管舒缩症状的治疗 Download PDF

Info

Publication number
CN101801380A
CN101801380A CN200880106932A CN200880106932A CN101801380A CN 101801380 A CN101801380 A CN 101801380A CN 200880106932 A CN200880106932 A CN 200880106932A CN 200880106932 A CN200880106932 A CN 200880106932A CN 101801380 A CN101801380 A CN 101801380A
Authority
CN
China
Prior art keywords
vasomotor symptoms
acid
flibanserin
vasomotor
symptoms associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN200880106932A
Other languages
English (en)
Other versions
CN101801380B (zh
Inventor
弗拉迪米尔·黑尼斯
安妮丽斯·维比克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40019339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101801380(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN101801380A publication Critical patent/CN101801380A/zh
Application granted granted Critical
Publication of CN101801380B publication Critical patent/CN101801380B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

本发明涉及一种治疗血管舒缩症状的方法，该方法包括给药治疗有效量的氟班色林。

Description

血管舒缩症状的治疗
本发明涉及治疗与绝经有关的血管舒缩症状的方法，该方法包括给药治疗有效量的氟班色林。
发明详述
化合物1-[2-(4-(3-三氟甲基-苯基)哌嗪-1-基)乙基]-2，3-二氢-1H-苯并咪唑-2-酮(氟班色林(flibanserin))以盐酸盐的形式公开于欧洲专利申请EP-A-526434，并具有以下化学结构：
Figure GPA00001055797900011
氟班色林对5-HT1A和5-HT2-受体显示亲合力。因此，对于治疗例如抑郁、精神分裂症和焦虑的各种疾病，其是一种具有前景的治疗剂。
经历绝经的妇女常常感受到由卵巢衰竭导致的雌激素丧失而引起的各种症状。绝经定义为妇女月经停止。绝经时间事后才知道，在闭经后十二个月得以确定。大多数妇女在40岁至55岁之间经历绝经。绝经过渡期(menopausal transition)的特征在于：潮热、头痛、盗汗、萎缩性阴道炎、频繁尿道感染、手脚发冷、健忘和注意力分散。绝经过渡期的情绪表现包括焦虑、沮丧、烦躁不安、情绪波动、抑郁和性冲动减少。当女性经历绝经时，因身体变化造成的不良症状繁多至无法详述。
一些症状(如外阴和阴道萎缩)可明确地归因于雌激素不足；然而，潮热很可能是位于下丘脑前部中枢神经系统体温调定点变化的结果。潮热(hotflashes)(又名″血管舒缩潮热(vasomotor flushes)″或″潮热(hot flushes)″)在绝经前和绝经后妇女中很常见。潮热期间，外周血管扩张导致皮肤发红和变暖。进一步的症状如心率加快、盗汗、头痛、眩晕、体重增加、疲劳和失眠可能与潮热有关。潮热可以出现于月经停止之前，并可能是绝经临近的首要体征。在绝经前期期间，约75％的妇女主诉潮热。在此类大多数妇女中，该症状将持续约1年。大约三分之一的绝经后妇女报告，在自然绝经后，该症状持续达5年，20％或更多的妇女潮热持续达15年。手术引起的绝经在第一年期间发生潮热的可能性约为90％，与非手术绝经有关的潮热相比，与手术有关的潮热常常为更急剧且严重，并持续更久。
美国人口普查局(US Bureau of Census)估计当前有49,000,000位美国妇女年龄超过50岁。因此，在美国，当今超过32,000,000位妇女可能已经出现潮热，且达到6,000,000位可能已经报告有严重的症状。
现在，来自严重抑郁症(Major Depressive Disorder)病人研究的实验结果已显示氟班色林可用于治疗血管舒缩症状(vasomotor symptoms)(如潮热(hotflashes)、盗汗(night sweats)、情绪波动(moodswings)和烦躁不安(irritability))。
因此，本发明涉及一种治疗血管舒缩症状的方法，其包括给药治疗有效量的氟班色林，任选以其游离碱、其药理学上可接受的酸加成盐的形式和/或任选以其水合物和/或溶剂合物的形式。
在另一方面，本发明涉及一种治疗与绝经过渡期有关的血管舒缩症状的方法，其包括给药治疗有效量的氟班色林，任选以其游离碱、其药理学上可接受的酸加成盐的形式和/或任选以其水合物和/或溶剂合物的形式。
血管舒缩症状的出现并不仅仅由于自然发生的绝经，而且也可能由于手术(例如子宫切除和双侧卵巢切除)引起的绝经或使用药物(例如使用选择性雌激素受体调节剂、GnRH类似物和芳香化酶抑制剂)引起的绝经，或因放射和化疗剂引起的绝经，因此，本发明涉及一种治疗或预防与医源性引起的绝经(iatrogenic induced menopause)有关的血管舒缩症状的方法，其包括给药治疗有效量的氟班色林，任选以其游离碱、其药理学上可接受的酸加成盐的形式和/或任选以其水合物和/或溶剂合物的形式。
在另一个实施方案中，本发明涉及一种治疗潮热、盗汗、情绪波动和烦躁不安的方法，其包括给药治疗有效量的氟班色林，任选以其游离碱、其药理学上可接受的酸加成盐的形式和/或任选以其水合物和/或溶剂合物的形式。
本发明的另一方面涉及氟班色林用于治疗与男性自然或医源性性腺机能减退(natural or iatrogenic hypogonadal state in men)有关的中度至重度血管舒缩症状的用途。
本发明另一方面涉及氟班色林用于治疗男性潮热(优选在性腺机能减退的男性中)，以及因治疗而丧失雄激素或接受阉割的男性的用途。
本发明的另一个实施方案涉及氟班色林，任选以其游离碱、其药理学上可接受的酸加成盐的形式和/或任选以其水合物和/或溶剂合物的形式在制备用于治疗上述任一疾病的药物中的用途。
如上所述，氟班色林可以其游离碱的形式、任选以其药理学上可接受的酸加成盐的形式和/或任选以其水合物和/或溶剂合物的形式使用。适宜的酸加成盐包括例如那些与选自下列的酸所形成的酸加成盐：琥珀酸、氢溴酸、乙酸、富马酸、马来酸、甲磺酸、乳酸、磷酸、盐酸、硫酸、酒石酸和柠檬酸。也可使用上述酸加成盐的混合物。在上述酸加成盐中，优选盐酸盐和氢溴酸盐，尤其优选盐酸盐。如果氟班色林以游离碱的形式使用，优选使用WO 03/014079所公开的氟班色林多晶型A的形式。
氟班色林，任选以其游离碱、其药理学上可接受的酸加成盐的形式和/或任选以其水合物和/或溶剂合物的形式，可以以固体、液体或者喷雾形式掺入至常规的药物制剂中。组合物可(例如)以适于口服、直肠、肠胃外给药或经鼻吸入的形式存在，优选的形式包括(例如)胶囊、片剂、包衣片剂、安瓿、栓剂和鼻喷雾剂。
活性成分可掺入至药物组合物中常规使用的赋形剂或载体中，例如，滑石、阿拉伯胶、乳糖、明胶、硬脂酸镁、玉米淀粉、水性或非水性溶媒、聚乙烯吡咯烷酮、半合成脂肪酸的甘油酯、苯扎氯铵、磷酸钠、EDTA、聚山梨酯80。该组合物有利地以剂量单位形式配制，每一剂量单位适于提供单一剂量的活性成分。每日的适宜剂量范围介于0.1至400mg之间，优选介于1.0至300mg之间，更有选介于2至200mg之间。每一剂量单位可适宜地包含0.01至100mg，优选0.1至50mg。
适宜的片剂可(例如)通过将活性物质与下述物质混合而获得，已知的赋形剂，例如，惰性稀释剂如碳酸钙、磷酸钙或乳糖，崩解剂如玉米淀粉或藻酸，粘合剂如淀粉或明胶，润滑剂如硬脂酸镁或滑石，和/或用于延迟释放的试剂如羧甲基纤维素、邻苯二甲酸乙酸纤维素或聚乙酸乙烯酯。片剂也可包含若干层。
包衣片剂可相应地通过使用片剂包衣通常使用的物质涂覆类似于片剂制备的片芯而制备，用于包衣的物质如：可力酮或虫胶、阿拉伯胶、滑石、二氧化钛或糖。为了达到延迟释放或防止不兼容性，片芯也可由许多层组成。同样地，该片剂包衣亦可由许多层组成以达到延迟释放，可使用如上所述用于片剂的赋形剂。
本发明的包含活性物质或其组合的糖浆或酏剂可以另外包含增甜剂，如糖精、甜蜜素(cyclamate)、甘油或糖，和风味增强剂，例如，香料如香兰素或香橙提取物。它们也可包含助悬剂或增稠剂，如羧甲基纤维素钠，润湿剂，如脂肪醇与环氧乙烷的缩合产物，或防腐剂，如对羟基苯甲酸酯。
注射用溶液按常规方法制备，例如，添加防腐剂如对羟基苯甲酸酯，或稳定剂如乙二胺四乙酸的碱金属盐，并转移入注射小瓶或安瓿中。
包含一种或多种活性物质或活性物质组合的胶囊可(例如)通过将活性物质与惰性载体如乳糖或山梨糖醇混合，并填充至明胶胶囊中而制备。
适宜的栓剂可(例如)通过将为此目的提供的载体，如中性脂肪或聚乙二醇或其衍生物混合而制备。
下面的实施例用于示例性地说明本发明，而不是对其范围进行限制：
实施例
临床试验
在确诊为严重抑郁症病人的12个II期临床研究中，超过1500名介于18至65岁之间的男性与女性受试者接受介于2mg至100mg之间(1天2次(b.i.d.))的一种或多种剂量的氟班色林。初步分析这些受试者的安全数据显示：相较于安慰剂(1.25％)或选择性5-羟色胺再吸收抑制剂(2.1％)，氟班色林基本上没有出现AE(以潮热/面红表示)。(参见表1)。
表1：
Figure GPA00001055797900041
表1中显示：接受安慰剂的718人中有9人(1.25％)、接受帕罗西汀(Paroxetine)的275人中有5人(1.8％)或接受氟西汀(Fluoxetine)的145人中有4人(2.75％)出现面红或潮热。形成鲜明对比的是：接受日剂量50至200mg氟班色林的802患者中仅有1人出现面红。
这些数据显示，氟班色林可用于治疗绝经妇女的血管舒缩症状如潮热。
药物制剂实施例
A)  片剂                       每片
    盐酸氟班色林               100mg
    乳糖                       240mg
    玉米淀粉                   340mg
    聚乙烯吡咯烷酮             45mg
    硬脂酸镁                   15mg          
                               740mg
将精细粉碎的活性物质、乳糖和一些玉米淀粉一起混合。将混合物过筛，然后使用聚乙烯吡咯烷酮于水中的溶液润湿、捏合、湿法制粒并干燥。将颗粒、剩余的玉米淀粉和硬脂酸镁过筛并混合。将混合物压制以制备适宜形状和大小的片剂。
B)  片剂                      每片
    盐酸氟班色林              80mg
    玉米淀粉                  190mg
    乳糖                      55mg
    微晶纤维素                35mg
    聚乙烯吡咯烷酮            15mg
    羧甲基淀粉钠              23mg
    硬脂酸镁                  2mg          
                              400mg
将精细粉碎的活性物质、一些玉米淀粉、乳糖、微晶纤维素和聚乙烯吡咯烷酮一起混合，将混合物过筛，并与剩余的玉米淀粉和水加工，形成颗粒，将其干燥并过筛。添加羧甲基淀粉钠和硬脂酸镁，并混合，将混合物压制以制备适宜大小的片剂。
C)包衣片剂                       每包衣片
  盐酸氟班色林                   5mg
  玉米淀粉                       41.5mg
  乳糖                           30mg
  聚乙烯吡咯烷酮                 3mg
  硬脂酸镁                       0.5mg          
                                 80mg
将活性物质、玉米淀粉、乳糖和聚乙烯吡咯烷酮均匀混合，并用水润湿。将该润湿的物质通过1毫米网目的筛网，在大约45℃干燥，然后将该颗粒再通过相同的筛网。与硬脂酸镁混合后，在制片机中压制成6毫米直径的凸面片剂片芯。按照已知方式使用基本上由糖和滑石组成的包覆层包衣所制造的片剂片芯。使用蜡抛光制成的片剂。
D)  胶囊                        每胶囊
    盐酸氟班色林                150mg
    玉米淀粉                    268.5mg
    硬脂酸镁                    1.5mg      
                                420mg
将该物质和玉米淀粉混合，并用水润湿。将该润湿物质过筛并干燥。将干燥颗粒过筛并与硬脂酸镁混合。将最终的混合物填充至1号硬明胶胶囊中。
E)  安瓿溶液
    盐酸氟班色林                      50mg
    氯化钠                            50mg
    注射用水                          5ml
将活性物质以其自身pH或任选在pH5.5至6.5溶于水中，并添加氯化钠使其等渗。将所得的溶液过滤，以去除致热原，并在无菌条件下将滤液转移至安瓿，然后将其杀菌并熔融密封。
F)  栓剂
    盐酸氟班色林                      50mg
    固体脂肪                          1650mg        
                                      1700mg
将硬质脂肪熔化。在40℃，将研磨的活性物质均匀地分散。将其冷却至38℃，并倒入至稍冷的栓剂模型中。
在本发明的一个特别优选的实施方案中，氟班色林以特定的膜包衣片剂的形式给药。这些优选制剂的实例列于下文。如下所列的膜包衣片剂可按照现有技术中已知的方法制造(参考WO 03/097058)。
G)膜包衣片剂
片芯
  成分   mg/片
  氟班色林   25.000
  乳糖单水合物   71.720
  微晶纤维素   23.905
  HPMC(Methocel E5(甲基纤维素E5))   1.250
  羧甲基纤维素钠   2.500
  硬脂酸镁   0.625
包衣
  成分   mg/片剂
  HPMC(Methocel E5)   1.440
  聚乙二醇6000   0.420
  二氧化钛   0.600
  滑石   0.514
  氧化铁红   0.026
  膜包衣片剂总重   128.000
H)膜包衣片剂
片芯
  成分   mg/片剂
  氟班色林   50.000
  乳糖单水化物   143.440
  微晶纤维素   47.810
  HPMC(例如Pharmacoat 606)   2.500
  羧甲基纤维素钠   5.000
  硬脂酸镁   1.250
包衣
  成分   mg/片剂
  HPMC(例如Pharmacoat 606)   2.400
  聚乙二醇6000   0.700
  二氧化钛   1.000
  滑石   0.857
  成分   mg/片剂
  氧化铁红   0.043
  膜包衣片剂总重   255.000
I)膜包衣片剂
片芯
  成分   mg/片剂
  氟班色林   100.000
  乳糖单水化物   171.080
  微晶纤维素   57.020
  HPMC(例如Methocel E5)   3.400
  羧甲基纤维素钠   6.800
  硬脂酸镁   1.700
包衣
  成分   mg/片剂
  HPMC(例如Methocel E5)   3.360
  聚乙二醇6000   0.980
  二氧化钛   1.400
  滑石   1.200
  氧化铁红   0.060
  膜包衣片剂总重   347.000
J)膜包衣片剂
片芯
  成分   mg/片剂
  氟班色林   2.000
  无水磷酸氢钙   61.010
  微晶纤维素   61.010
  HPMC(Methocel E5)   1.950
  羧甲基纤维素钠   2.600
  胶体二氧化硅   0.650
  硬脂酸镁   0.780
包衣
  成分   mg/片剂
  HPMC(Methocel E5)   1.440
  聚乙二醇6000   0.420
  二氧化钛   0.600
  滑石   0.514
  氧化铁红   0.026
  膜包衣片剂总重   133.000
K)膜包衣片剂
片芯
  成分   mg/片剂
  氟班色林   100.000
  成分   mg/片剂
  无水磷酸氢钙   69.750
  微晶纤维素   69.750
  HPMC(例如Methocel E5)   2.750
  羧甲基纤维素钠   5.000
  胶体二氧化硅   1.250
  硬脂酸镁   1.500
包衣
  成分   mg/片剂
  HPMC(例如Methocel E5)   2.400
  聚乙二醇6000   0.700
  二氧化钛   1.043
  滑石   0.857
  膜包衣片剂总重   255.000
L)膜包衣片剂
片芯
  成分   mg/片剂
  氟班色林   20.000
  乳糖单水化物   130.000
  微晶纤维素   43.100
  羟丙基纤维素(例如Klucel LF)   1.900
  成分   mg/片剂
  淀粉羟乙酸钠   4.000
  硬脂酸镁   1.000
包衣
  成分   mg/片剂
  HPMC(例如Methocel E5)   2.400
  聚乙二醇6000   0.700
  二氧化钛   1.043
  滑石   0.857
  膜包衣片剂总重   205.000

Claims (12)

1.一种治疗血管舒缩症状的方法，所述方法包括给药治疗有效量的氟班色林，任选以其游离碱、其药理学上可接受的酸加成盐的形式和/或任选以其水合物和/或溶剂合物的形式。
2.权利要求1的方法，其特征在于所述血管舒缩症状为与绝经有关的血管舒缩症状。
3.权利要求1的方法，其特征在于所述血管舒缩症状为与手术引起的绝经有关的血管舒缩症状。
4.权利要求1的方法，其特征在于所述血管舒缩症状为与医源性引起的绝经有关的血管舒缩症状。
5.权利要求1或4的方法，其特征在于所述血管舒缩症状为与药物、放射或化疗剂使用有关的血管舒缩症状。
6.权利要求1的方法，其特征在于所述血管舒缩症状选自潮热、盗汗、情绪波动和烦躁不安。
7.权利要求1的方法，其特征在于所述血管舒缩症状选自与男性自然或医源性性腺机能减退有关的中度至重度血管舒缩症状。
8.权利要求7的方法，其特征在于所述血管舒缩症状为与药物、放射或化疗剂使用有关的血管舒缩症状。
9.权利要求7或8的方法，其特征在于所述血管舒缩症状为男性潮热。
10.权利要求1至9中任一项的方法，其特征在于所述氟班色林以可药用酸加成盐的形式施用，该酸加成盐选自与由下列酸所形成的酸加成盐：琥珀酸、氢溴酸、乙酸、富马酸、马来酸、甲磺酸、乳酸、磷酸、盐酸、硫酸、酒石酸、柠檬酸，及其混合物。
11.权利要求1至9中任一项的方法，其特征在于所述氟班色林以氟班色林多晶型A的形式施用。
12.权利要求1至9中任一项的方法，其特征在于所述氟班色林以每日0.1-400mg的剂量范围施用。
CN2008801069327A 2007-09-12 2008-09-11 血管舒缩症状的制药用途 Expired - Fee Related CN101801380B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97160507P 2007-09-12 2007-09-12
US60/971,605 2007-09-12
PCT/EP2008/062011 WO2009034111A1 (en) 2007-09-12 2008-09-11 Treatment of vasomotor symptoms

Publications (2)

Publication Number Publication Date
CN101801380A true CN101801380A (zh) 2010-08-11
CN101801380B CN101801380B (zh) 2013-05-08

Family

ID=40019339

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801069327A Expired - Fee Related CN101801380B (zh) 2007-09-12 2008-09-11 血管舒缩症状的制药用途

Country Status (22)

Country Link
US (6) US20110136825A1 (zh)
EP (1) EP2200614B1 (zh)
JP (1) JP2010539130A (zh)
KR (1) KR20100059848A (zh)
CN (1) CN101801380B (zh)
AR (1) AR068416A1 (zh)
AU (1) AU2008297104A1 (zh)
BR (1) BRPI0816791A2 (zh)
CA (1) CA2699414C (zh)
CL (1) CL2008002693A1 (zh)
CO (1) CO6260073A2 (zh)
EA (1) EA201000433A1 (zh)
ES (1) ES2444707T3 (zh)
MA (1) MA31757B1 (zh)
MX (1) MX2010002032A (zh)
NZ (1) NZ584183A (zh)
PE (1) PE20091188A1 (zh)
TN (1) TN2010000108A1 (zh)
TW (1) TW200927118A (zh)
UY (1) UY31335A1 (zh)
WO (1) WO2009034111A1 (zh)
ZA (1) ZA201000384B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108349908A (zh) * 2016-02-02 2018-07-31 深圳市塔吉瑞生物医药有限公司 一种取代的苯并咪唑酮化合物及包含该化合物的组合物

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
PL1912650T3 (pl) 2005-08-03 2018-01-31 Sprout Pharmaceuticals Inc Zastosowanie flibanseryny w leczeniu otyłości
ATE524446T1 (de) * 2006-12-20 2011-09-15 Boehringer Ingelheim Int Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität
CL2008002693A1 (es) * 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3096248A (en) * 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
US3406178A (en) * 1964-02-04 1968-10-15 Monsanto Chem Australia Ltd Preparation of 2-substituted benzimidazoles
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
US4200641A (en) * 1976-12-21 1980-04-29 Janssen Pharmaceutica, N.V. 1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives
AU521110B2 (en) 1978-06-20 1982-03-18 Synthelabo Phenylpiperazine derivatives
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3126703A1 (de) 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
JPS58134033A (ja) 1982-02-02 1983-08-10 Fujisawa Pharmaceut Co Ltd 医薬組成物
IT1176613B (it) * 1984-08-14 1987-08-18 Ravizza Spa Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
HUT43600A (en) 1985-06-22 1987-11-30 Sandoz Ag Process for production of new thiazole derivatives and medical compound containing those
DE3620643A1 (de) 1985-06-22 1987-01-22 Sandoz Ag Thiazole, ihre herstellung und verwendung
GB8601160D0 (en) * 1986-01-17 1986-02-19 Fujisawa Pharmaceutical Co Heterocyclic compounds
US5036088A (en) * 1986-06-09 1991-07-30 Pfizer Inc. Antiallergy and antiinflammatory agents, compositions and use
JPH0784462B2 (ja) * 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
GB8830312D0 (en) 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
US4954503A (en) * 1989-09-11 1990-09-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(1-substituted-4-piperazinyl)-1H-indazoles
AU8629691A (en) 1990-08-09 1992-03-02 Massachusetts Institute Of Technology Method for treating the premenstrual or late luteal phase syndrome
DE69129839T2 (de) 1990-08-24 1999-02-11 Shin-Etsu Chemical Co., Ltd., Tokio/Tokyo Beschichtungsbase für einen pharmazeutischen film und verfahren zur herstellung derselben
NZ241613A (en) * 1991-02-27 1993-06-25 Janssen Pharmaceutica Nv Highlighting intagliations in tablets
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
FR2675800A1 (fr) 1991-04-26 1992-10-30 Rhone Poulenc Rorer Sa Derives heterocycliques antiserotonines leur preparation et les medicaments les contenant.
HUT68769A (en) 1991-05-07 1995-07-28 Merck & Co Inc FIBRINOGéN RECEPTOR ANTAGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AS EFFECTIVE SUBSTANCE
IT1251144B (it) 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
DE4216364A1 (de) 1991-12-14 1993-11-25 Thomae Gmbh Dr K Neue Pyridylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5225417A (en) * 1992-01-21 1993-07-06 G. D. Searle & Co. Opioid agonist compounds
US5492907A (en) * 1992-12-09 1996-02-20 The United States Of America As Represented By The Department Of Health & Human Services Antipsychotic composition and method of treatment
DE69429768T2 (de) 1993-04-05 2002-09-19 Competitive Technologies, Inc. Diagnose und behandlung von erektilen funktionsstörungen
FR2707294B1 (fr) * 1993-07-06 1995-09-29 Pf Medicament Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine.
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
ATE206708T1 (de) 1994-06-14 2001-10-15 Pfizer Benzimidazolonderivate mit zentraler dopaminerger aktivität
PL181215B1 (pl) 1994-08-23 2001-06-29 Smithkline Beecham Plc Kompozycja farmaceutyczna zawierająca ibuprofen i kodeinę oraz sposób jej wytwarzania
ES2204932T3 (es) 1994-09-12 2004-05-01 Eli Lilly And Company Limited Moduladores serotonergicos.
JPH08143476A (ja) 1994-11-18 1996-06-04 Japan Tobacco Inc 薬物放出制御膜及び固形製剤
FR2727682A1 (fr) * 1994-12-02 1996-06-07 Pf Medicament Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5883094A (en) * 1995-04-24 1999-03-16 Pfizer Inc. Benzimidazolone derivatives with central dopaminergic activity
US5854290A (en) * 1995-09-21 1998-12-29 Amy F. T. Arnsten Use of guanfacine in the treatment of behavioral disorders
US6083947A (en) * 1996-01-29 2000-07-04 The Regents Of The University Of California Method for treating sexual dysfunctions
GB9613423D0 (en) 1996-06-26 1996-08-28 Lilly Industries Ltd Pharmaceutical compounds
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
WO1998019668A1 (en) 1996-11-06 1998-05-14 Sharmatek, Inc. Delayed delivery system for acid-sensitive drugs
JP2001504851A (ja) * 1996-12-02 2001-04-10 メルク シヤープ エンド ドーム リミテツド 性的機能不全の治療のためのｎｋ−１受容体拮抗薬の使用
US5859246A (en) 1997-01-30 1999-01-12 Neurogen Corporation 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands
US20040023948A1 (en) * 1997-03-24 2004-02-05 Green Richard David Fast-dispersing dosage form containing 5-HT1 agonists
GB9706089D0 (en) 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
DE69826660T2 (de) * 1997-06-11 2005-10-06 The Procter & Gamble Company, Cincinnati Filmüberzogene tablette für verbesserte verträglichkeit im oberen magen-darmtrakt
DE69815003T2 (de) * 1997-09-10 2004-04-01 Takeda Chemical Industries, Ltd. Stabilisierte pharmazeutische Zusammensetzung
SE9703375D0 (sv) 1997-09-18 1997-09-18 Astra Ab A new combination
CH692199A8 (fr) 1997-10-09 2002-06-14 Cermol S.A. Composes pyridiques et compositions pharmaceutique
JP3724157B2 (ja) * 1997-10-30 2005-12-07 コニカミノルタホールディングス株式会社 映像観察装置
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
WO1999059584A1 (en) 1998-05-20 1999-11-25 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
JP2002515435A (ja) 1998-05-21 2002-05-28 イーライ・リリー・アンド・カンパニー 鬱病処置のための組合せ治療
US20020151543A1 (en) * 1998-05-28 2002-10-17 Sepracor Inc. Compositions and methods employing R (-) fluoxetine and other active ingredients
EP1085869A4 (en) 1998-06-11 2001-10-04 Merck & Co Inc Spiropiperidine derivatives as melanocortin receptor agonists
US6068846A (en) * 1998-08-05 2000-05-30 Melaleuca, Incorporated Methods and materials for treating depression and mood disorder
EP0982030A3 (en) 1998-08-17 2000-05-10 Pfizer Products Inc. 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands
UA67802C2 (uk) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
AU1738900A (en) 1998-11-19 2000-06-05 Nortran Pharmaceuticals Inc. Serotonin ligands as pro-erectile compounds
US6680071B1 (en) * 1999-03-03 2004-01-20 R. P. Scherer Technologies, Inc. Opioid agonist in a fast dispersing dosage form
WO2000063189A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate
CN1461216A (zh) 1999-04-28 2003-12-10 呼吸器有限公司 用作治疗有关支气管收缩的机能障碍的药物的化合物
IT1312310B1 (it) 1999-05-07 2002-04-15 Recordati Ind Chimica E Farma Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US20030055070A1 (en) 1999-07-01 2003-03-20 Wilma Harrison Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
IT1313625B1 (it) 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
NZ520975A (en) * 2000-02-24 2004-03-26 Upjohn Co New drug combinations containing a norepinephrine reuptake inhibitor and an antimuscarinic agent for treating nervous system disorders
AP2001002196A0 (en) 2000-06-28 2002-12-21 Pfizer Prod Inc Melanocortin receptor ligands.
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
US20020052370A1 (en) 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6521623B1 (en) * 2000-09-19 2003-02-18 Boehringer Ingelheim Pharma Kg N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
US6586435B2 (en) * 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
ES2273891T3 (es) 2000-09-19 2007-05-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Nuevos derivados de bencimidazolona que presentan actividad en los receptores de serotonina y dopamina.
BR0110450A (pt) 2000-11-22 2005-02-09 Abbott Lab Uso de agonistas receptores d4 de dopamina seletivo para tratamento de disfunção sexual
GB0105893D0 (en) 2001-03-09 2001-04-25 Pfizer Ltd Pharmaceutically active compounds
GB0106446D0 (en) 2001-03-15 2001-05-02 Vernalis Res Ltd Chemical compounds
RS75303A (sr) 2001-03-28 2006-12-15 Pfizer Limited Derivati n-fenilpropilciklopentil-supstituisanog glutaramida kao nep inhibitori za fsad
EP1256343B1 (en) 2001-05-11 2006-07-05 Jürgen K. Dr. Beck Flibanserin for the treatment of extrapyramidal movement disorders
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
CA2453609C (en) 2001-07-18 2010-05-04 Merck & Co., Inc. Bridged piperidine derivatives as melanocortin receptor agonists
EP1412028B1 (en) 2001-07-30 2007-10-17 Spectrum Pharmaceuticals, Inc. Tetrahydroindolone derivatives linked to arylpiperazines
AU2002331361B2 (en) 2001-08-02 2008-06-05 Sprout Pharmaceuticals, Inc. Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
DE10138273A1 (de) 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
HUP0202719A3 (en) 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
DE10209982A1 (de) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
CN1655789A (zh) 2002-05-22 2005-08-17 贝林格尔英格海姆法玛两合公司 新型含氟班色林多晶型物a的药物组合物
MXPA05000294A (es) 2002-07-30 2005-08-19 Peter Migaly Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
US20040132697A1 (en) * 2002-11-06 2004-07-08 Pfizer Inc. Treatment of female sexual dysfunction
GB0225908D0 (en) 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
US20040193452A1 (en) * 2003-01-06 2004-09-30 Laura Berman Method and system for computerized sexual function assessment of female users
US20050004105A1 (en) * 2003-01-29 2005-01-06 Emer Leahy Treatment for a attention-deficit hyperactivity disorder
US20050037983A1 (en) 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
US7227023B2 (en) * 2003-04-30 2007-06-05 Wyeth Quinoline 3-amino chroman derivatives
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
EP1653966A1 (en) 2003-07-16 2006-05-10 Pfizer Limited Treatment of sexual dysfunction
CA2537837A1 (en) 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
WO2005044238A1 (en) 2003-11-07 2005-05-19 Ranbaxy Laboratories Limited Modified release solid dosage form of amphetamine salts
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
AU2005235422B2 (en) * 2004-04-22 2011-08-11 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders II
US20060014757A1 (en) 2004-07-14 2006-01-19 Boehringer Ingelheim Pharmaceuticals Method for the treatment of anorexia nervosa
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
JP2008511569A (ja) * 2004-09-03 2008-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 注意欠如活動過多障害の治療方法
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
EP1858515A2 (en) 2005-03-04 2007-11-28 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
CA2599721A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
WO2006119884A2 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
US20060258640A1 (en) * 2005-05-13 2006-11-16 Boehringer Ingelheim International Gmbh Use of Flibanserin in the treatment of chronic pain
EP1888071A1 (en) * 2005-05-19 2008-02-20 Boehringer Ingelheim International GmbH Method for the treatment of drug-induced sexual dysfunction
CA2608713A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunctions due to medical conditions
US7241805B2 (en) 2005-06-27 2007-07-10 Biovail Laboratories, Inc. Modified release formulations of a bupropion salt
PL1912650T3 (pl) * 2005-08-03 2018-01-31 Sprout Pharmaceuticals Inc Zastosowanie flibanseryny w leczeniu otyłości
HU227490B1 (en) 2005-08-26 2011-07-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Sustained release pharmaceutical preparation containing carvedilol
WO2007048803A1 (en) 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
NZ569984A (en) 2006-01-27 2011-06-30 Eurand Inc Drug delivery systems comprising weakly basic drugs and organic acids
US20090023712A1 (en) * 2006-02-18 2009-01-22 Boehringer Ingelheim International Gmbh Pharmaceutical Compositions for the Treatment of Attention Deficit Hyperactivity Disorder Comprising Flibanserin
EP1988897A1 (en) * 2006-02-20 2008-11-12 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of urinary incontinence
JP2009528322A (ja) * 2006-02-28 2009-08-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フリバンセリンによる弁膜性心疾患の治療又は予防
RS54398B1 (sr) * 2006-05-09 2016-04-28 Sprout Pharmaceuticals, Inc. Upotreba flibanserina za lečenje poremećaja seksualne želje u postmenopauzi
JP2009541443A (ja) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
CA2657045A1 (en) * 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Combinations of flibanserin with caffeine, process for their preparation and use thereof as medicaments
US20090318469A1 (en) 2006-07-14 2009-12-24 Boehringer Ingelheim International Gmbh Use of Flibanserin for the Treatment of Sexual Disorders in Females
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
CA2660476C (en) * 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
KR20090045945A (ko) * 2006-08-25 2009-05-08 베링거 인겔하임 인터내셔날 게엠베하 제어 방출 시스템 및 이의 제조방법
ATE524446T1 (de) 2006-12-20 2011-09-15 Boehringer Ingelheim Int Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität
US20100093754A1 (en) 2007-03-28 2010-04-15 Boehringer Ingelheim International Gmbh Pharmaceutical Compositions Comprising Flibanserin and a Further Agent in the Treatment of Sexual Disorders
CL2008002693A1 (es) * 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108349908A (zh) * 2016-02-02 2018-07-31 深圳市塔吉瑞生物医药有限公司 一种取代的苯并咪唑酮化合物及包含该化合物的组合物
CN108349908B (zh) * 2016-02-02 2021-07-20 深圳市塔吉瑞生物医药有限公司 一种取代的苯并咪唑酮化合物及包含该化合物的组合物

Also Published As

Publication number Publication date
US9949969B2 (en) 2018-04-24
CN101801380B (zh) 2013-05-08
CA2699414A1 (en) 2009-03-19
WO2009034111A1 (en) 2009-03-19
MX2010002032A (es) 2010-03-15
BRPI0816791A2 (pt) 2019-09-24
US10166230B2 (en) 2019-01-01
ZA201000384B (en) 2010-09-29
CO6260073A2 (es) 2011-03-22
US20140005203A1 (en) 2014-01-02
EA201000433A1 (ru) 2010-10-29
JP2010539130A (ja) 2010-12-16
US20180071283A1 (en) 2018-03-15
AR068416A1 (es) 2009-11-18
CA2699414C (en) 2016-04-05
UY31335A1 (es) 2009-04-30
PE20091188A1 (es) 2009-08-31
US20150250783A1 (en) 2015-09-10
NZ584183A (en) 2012-05-25
MA31757B1 (fr) 2010-10-01
US20200253962A1 (en) 2020-08-13
ES2444707T3 (es) 2014-02-26
AU2008297104A1 (en) 2009-03-19
EP2200614B1 (en) 2013-11-27
US10596170B2 (en) 2020-03-24
US20110136825A1 (en) 2011-06-09
EP2200614A1 (en) 2010-06-30
TN2010000108A1 (fr) 2011-09-26
TW200927118A (en) 2009-07-01
CL2008002693A1 (es) 2009-10-16
US20190091219A1 (en) 2019-03-28
KR20100059848A (ko) 2010-06-04

Similar Documents

Publication Publication Date Title
US10307420B2 (en) Treating sexual desire disorders with flibanserin
RU2384333C2 (ru) Применение флибансерина для лечения предменструальных и иных сексуальных расстройств у женщин
US10596170B2 (en) Treatment of vasomotor symptoms
AU2002333894A1 (en) Use of flibanserin in the treatment of sexual disorders
JP2008506688A (ja) 神経性無食欲症の治療方法
JP2008540672A (ja) 病状に起因する性的機能不全の治療方法
JP2008511569A (ja) 注意欠如活動過多障害の治療方法
US10675280B2 (en) Treating sexual desire disorders with flibanserin
HK1131059A (zh) 氟班色林於治疗绝经後性慾障碍的用途
CN101443011A (zh) 氟班色林于治疗绝经后性欲障碍的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130508

Termination date: 20150911

EXPY Termination of patent right or utility model